Oncolytics Biotech's GOBLET Study Shows Promising Results for SCAC Treatment with Pelareorep

Oncolytics Biotech's Promising GOBLET Study Results for SCAC Treatment

Oncolytics Biotech Inc. has recently announced significant findings from its GOBLET study, which investigates the efficacy of pelareorep in combination with atezolizumab (Tecentriq®) for patients with squamous cell anal carcinoma (SCAC) who have undergone second-line or later treatments. This innovative therapeutic approach achieves an objective response rate (ORR) of 30%, a notable improvement compared to the 13.8% ORR associated with the currently FDA-approved immunotherapy for this condition. Among the 20 evaluable patients in the study, six show a positive treatment response, including two remarkable durable complete responses—one lasting over two years and the other for 15 months. These results signal a potential breakthrough in the treatment landscape for SCAC, particularly for patients with limited options.

The GOBLET study indicates that the median duration of response for patients treated with the combination therapy stands at 15.5 months, significantly longer than the 9.5 months seen with existing standard care. Jared Kelly, the CEO of Oncolytics, emphasizes that these outcomes represent the strongest efficacy signal observed with a non-chemotherapy regimen in anal cancer to date, underscoring the potential of pelareorep to elicit profound and sustained immune responses. This study marks a critical step forward in addressing a rare and challenging disease where treatment alternatives are scarce, primarily relying on chemotherapy.

Looking ahead, Oncolytics plans to engage with the FDA in Q1 2026 to discuss the possibility of a single-arm accelerated approval study based on the promising GOBLET study results. This strategy aligns with the company's goal of establishing pelareorep as a vital treatment option for SCAC patients, who currently face limited therapeutic alternatives. Furthermore, the SCAC cohort is part of a broader Phase 1/2 GOBLET trial exploring pelareorep alongside checkpoint inhibitors across various gastrointestinal cancers, including pancreatic and colorectal cancers, as Oncolytics seeks to enhance treatment outcomes for patients grappling with these challenging conditions.

In addition to the SCAC findings, Oncolytics is strategically positioned to leverage these results to advance its clinical development strategy. The focus on gastrointestinal tumors, where treatment options remain limited, highlights the importance of innovative therapies like pelareorep in reshaping the therapeutic landscape. As the company prepares for discussions with regulatory authorities, the momentum from the GOBLET study could pave the way for significant advancements in the treatment of gastrointestinal cancers.